Lyell Immunopharma, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $36,000 | $61,000 | $130,000 | $84.7M | $10.7M |
| Operating income | -$269.4M | -$358.8M | -$247.0M | -$187.1M | -$214.8M |
| Operating expenses | $269.4M | $358.8M | $247.1M | $271.7M | $225.4M |
| Cash from operations | -$150.0M | -$162.4M | -$163.7M | -$169.6M | -$126.2M |
| Capital expenditure | $780,000 | $464,000 | $2.7M | $24.3M | $65.5M |
| Free cash flow | -$150.8M | -$162.9M | -$166.4M | -$193.8M | -$191.8M |
| Share repurchases | — | — | — | $0 | $0 |
| Impairments | $1.4M | $51.3M | $0 | $0 | $0 |
| Total assets | $340.1M | $490.9M | $750.0M | $937.6M | $1.1B |
| Total liabilities | $91.8M | $108.0M | $95.1M | $104.3M | $197.6M |
Shares outstanding 23.3M
Annual filing data through FY ended December 31, 2025; float as of July 2, 2026.